EichorEICHOR
Study identifier: NCT05645276 Synced from ClinicalTrials.gov · August 05, 2026
● Recruiting

A Study of AK129 in Patients With Advanced Malignant Tumors

Condition: Advanced Malignant Tumors(Stage IA-IB)  ·  Sponsor: Akeso

PhasePhase 1
Planned participants182
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

A Phase Ia/Ib, open label, dose escalation and dose extension trial of Anti-PD-1 and LAG-3 bispecific antibody, AK129, to evaluate the safety, tolerability and antitumor efficacy in patients with advanced malignant tumors

This description comes directly from the study's public registry record.

Talk to the study team

Xiao Xu, MD, PhD  ·  +86 (0760) 8987 3999  ·  clinicaltrials@akesobio.com

Always discuss trial participation with your own doctor first.

Locations (1)

Cancer Hospital Chinese Academy of Medical ScienceBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05645276